The prEserveD left ventricular ejectIon fraction chronic heart Failure with ivabradine studY (EDIFY) included 179 patients in New York Heart Association (NYHA) classes II and III, in sinus rhythm, with HR of ≥70 b.p.m., NT-proBNP of ≥220 pg/mL (BNP ≥80 pg/mL) and left ventricular ejection fraction of ≥45%. Ivabradine (or placebo) was titrated to 7.5 mg b.i.d. Patients were followed for 8 months on the change and assessed for three co-primary endpoints: echo-Doppler E/e ′ ratio, distance on the 6-min walking test (6MWT), and plasma NT-proBNP concentration. At baseline, median E/e ′ was 12. 
Introduction
Heart failure with preserved ejection fraction (HFpEF) accounts for up to 50% of the incidence of heart failure and its prevalence is rising as a result of the ageing of populations.
1 No treatment has yet been shown to be effective in reducing morbidity and mortality in HFpEF.
An elevated heart rate (HR) is a predictive factor of worse outcomes and increased mortality in patients with heart failure, including in HFpEF. 2, 3 Ivabradine is a specific and selective inhibitor of the sino-atrial node I f current, 4 and thereby decreases HR. 5 In heart failure with reduced ejection fraction (HFrEF), ivabradine significantly reduced the risk for cardiovascular death and/or hospital admission for worsening heart failure 6 associated with a significant anti-remodelling effect. 7 In HFpEF animal models, ivabradine was shown to reduce cardiac fibrosis 8 and improve vascular stiffness, and left ventricular systolic and diastolic function. 9 Two small clinical studies in patients showed contradictory outcomes.
10,11
In the proof-of-concept study EDIFY (prEserveD left ventricular ejectIon fraction chronic heart Failure with ivabradine studY), we studied whether HR reduction with ivabradine improves diastolic function and exercise capacity and reduces NT-proBNP concentration in patients with HFpEF.
Methods

Study design and patients
EDIFY was a randomized, double-blind, placebo-controlled trial undertaken in 86 centres in 19 countries. Eligible patients were required to be aged 50 years or older, in sinus rhythm with a resting HR of 70 b.p.m. or higher (as measured by 12-lead electrocardiography), to have a history of symptomatic chronic heart failure [New York Heart Association (NYHA) class II or III] of at least 3 months, and to be in a stable clinical condition. Patients had to be able to perform a 6-min walking test (6MWT) but not to exceed 450 m. Eligibility criteria included a plasma concentration of NT-proBNP of ≥300 pg/mL (or BNP ≥100 pg/mL), left ventricular ejection fraction (LVEF) of ≥50% and at least one predefined echocardiographic criterion related to diastolic dysfunction as evaluated by the investigating site [echo-Doppler E/e ′ ratio of >13, or e ′ lateral <10 cm/s and e ′ septal <8 cm/s, or indexed volume of the left atrium (LAVI) of >34 mL/m 2 , where E/e ′ = ratio of peak early diastolic mitral flow velocity divided by the mean of the annular lateral (e ′ lateral) and septal (e ′ septal) velocities]. Nine months after the study start, to counter the low recruitment rate, the acceptance thresholds for NT-proBNP and BNP were decreased to 220 pg/mL and 80 pg/mL, respectively, and the LVEF threshold to ≥45%.
The main exclusion criteria were severe valvular disease, primary hypertrophic or restrictive cardiomyopathy and systemic illness associated with infiltrative heart disease, permanent atrial fibrillation or recent (<3 months) atrial fibrillation-related hospitalization, pacemaker carriage, severe or uncontrolled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg).
Treatments not allowed at inclusion and during the study included non-dihydropyridine calcium channel blockers, class I anti-arrhythmics and strong inhibitors of cytochrome P450 3A4 (see supplementary material online, Appendix S2, for full inclusion and exclusion criteria. The study conformed to the principles outlined in the Declaration of Helsinki and was approved by the ethics committee or institutional review board of each participating site. All patients provided written informed consent before randomization. The trial was conducted under the supervision of an independent executive committee (Supplementary material online, Appendix S3), the members of which were blinded to study medication. After the study unblinding, this committee was given full access to the data and analyses and was responsible for the interpretation of the results and review of the manuscript. A data-monitoring committee, unblinded to study medication, reviewed the trial data for patient safety at regular intervals.
The trial was registered in the European Clinical Trials Database (EudraCT no. 2012 002742 20).
Randomization
The study outline is presented in Figure 1 . After a single-blind placebo run-in period of 14 days, patients who fulfilled the criteria for enrolment were randomly assigned to ivabradine or placebo. The randomization was balanced (1:1) and stratified on centres. Study investigators and participants were masked to treatment for the duration of the trial.
Procedures
At randomization, the starting dose was ivabradine or matching placebo at 5 mg b.i. Three co-primary endpoints were defined: E/e ′ , total distance on 6MWT and plasma NT-proBNP concentration over an 8-month treatment period that extended from baseline to the last post-baseline value.
Secondary endpoints included other echocardiographic parameters to assess cardiac functional and structural parameters including total mitral flow duration (filling time), indexed left ventricular end-diastolic volume, stroke volume, LAVI, E, lateral e ′ , septal e ′ , mean of lateral and septal e ′ , indexed left ventricular mass and Ea/Ees (ratio of arterial elastance/ventricular end-systolic elastance). Other secondary endpoints were HR, NYHA class and quality of life as assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ). The occurrence of emergent adverse events was also assessed.
Echocardiography was performed at the selection visit and at months 2 and 8 or at early termination visits, according to international recommendations. 12, 13 Echocardiographic recordings were centralized (Biomedical Systems, Brussels, Belgium) and read independently by a blinded core laboratory supervised by the executive committee's echocardiographic expert (La Pitié Salpêtrière Hospital, Paris, France). Participating sonographers were certified by the core laboratory before the start of recruitment.
The 6MWT was performed at selection, at randomization, and at months 2, 4 and 8 or at early termination visits.
To assess the eligibility of potential subjects, NT-proBNP (or BNP if available) was measured in local laboratories, and was then measured centrally as NT-proBNP at randomization, and at months 2, 4 and 8 or at early termination visits (Laboratory BARC, Evry, France).
Statistical analysis
Baseline characteristics were summarized as the number In order to estimate the effects of study treatment on the three co-primary endpoints, ivabradine was compared with placebo on the change from baseline to the last post-baseline value on the 8-month treatment period using the last observation carried forward method. The main analysis was performed using an analysis of covariance (ANCOVA) model. Adjustments to the model were made on the fixed categorical effects of treatment and geographic area, as well as the continuous covariate of baseline. The data for NT-proBNP were log-transformed before analysis by ANCOVA. The Hommel procedure was used to correct for the multiplicity of testing with a two-sided type I error set at 10%. Results are presented as estimates (E) with associated standard errors (SE), two-sided 90% confidence intervals (CI), and adjusted P-values according to the Hommel procedure. Secondary efficacy endpoints were analysed using the same ANCOVA model without adjustment for multiplicity (post hoc analysis). Results are presented with estimates and 90% CIs. SAS version 9.2 (SAS Institute, Inc., Cary, NC, USA) was used for all analyses. Incidences of emergent adverse events were compared using a two-sided Fisher's exact test (post hoc analysis).
Calculation of the sample size was based on the following assumptions for NT-proBNP (the parameter with the largest variability). For a common standard deviation of 0.83 for the log-scale of the ratio of 8-month NT-proBNP over baseline between treatment groups, 176 patients per group were necessary to detect at least a 25% reduction in the ratio of 8-month NT-proBNP over baseline between treatment groups with 80% power, using a two-sided t-test on the logarithm of this ratio.
14 Hence, the study was required to include approximately 400 patients taking into account a 10% withdrawal rate.
Role of the funding source
The EDIFY trial was sponsored by Les Laboratoires Servier (Suresnes, France). The sponsor was responsible for study management, data collection and data analysis. 
Results
Study patients, drug administration and follow-up
A total of 654 patients were screened and 179 were randomized. The trial profile is shown in Figure 2 . Patients were recruited between 25 June 2013 and 7 July 2015. The last visit of the last patient took place on 29 February 2016. The main reasons for non-selection or non-inclusion were: NT-proBNP/BNP concentrations below threshold values; not in sinus rhythm; HR of <70 b.p.m., and failure to meet echocardiographic criteria (either relevant structural heart disease or mitral flow velocities). Recruitment was challenging and despite adaptations to the eligibility criteria (in NT-proBNP/BNP and LVEF thresholds) and the extension of the recruitment period for 8 months, the recruitment of 400 patients was not achieved.
The randomization provided fairly well-balanced treatment groups: 95 patients were assigned to ivabradine and 84 to placebo. The 8-month follow-up was completed by 80% of patients in the ivabradine group and 92% of those in the placebo group. The median duration of follow-up (randomized set) was 241 days (IQR: 237-246 days) with no relevant difference between the groups. Of the patients randomized to ivabradine, 46 (48.4%) were titrated up to 7.5 mg b.i.d., which was maintained until 8 months or the termination visit; 12 patients (12.6%) received 10 mg b.i.d. before the amendment (all 12 completed the study). The set of patients in Figure 3 Mean heart rate during the study by treatment group.
M1, month 1; M2, month 2; M4, month 4; M8, month 8.
whom efficacy endpoints were evaluated comprised 87 patients in the ivabradine group (eight patients were excluded as a result of missing post-baseline values) and 84 patients in the placebo group. The baseline characteristics of patients were comparable across the two treatment groups ( Table 1) .
Patients were elderly. Most patients were female, overweight, and in NYHA functional class II. Median HR was 75 b.p.m. and median LVEF was 60%. Blood pressure was well controlled (median sitting pressure: 132/77 mmHg). Most patients were taking an ACE inhibitor or angiotensin receptor blocker (ARB) and many were on diuretic drugs at baseline. Echocardiographic assessment at baseline showed reduced mitral annular relaxation velocity, enlarged left atria and left ventricular hypertrophy. In the majority of patients NT-proBNP was only slightly raised (median: 375 pg/mL; IQR: 253-701 pg/mL; geometric mean: 416 pg/mL). The baseline values for the three co-primary endpoints and their median changes to last post-baseline visit are presented in Table 2 . Inter-patient variability was wide at baseline for all endpoints and the observed changes over the treatment period were relatively small without any preponderant directionality. The between-group estimates of change showed no statistically significant results. Supplementary material online, Tables S1-S3, illustrate the effects of treatment in each of the patient subgroups based on a split either side of the median value at baseline for HR (≥75/<75 b.p.m.), E/e ′ (≥12.8/<12.8) and NT-proBNP (≥375/<375 pg/mL). No clear trends were observed in any of these comparisons. In terms of differential effect of treatment in patients with higher HR (≥75 b.p.m.), there was no relevant difference, with respect to the complementary subgroup, in E/e ′ change or in the other co-primary endpoints.
Study outcome
Other echocardiographic parameters are provided in Table 3 . There were significant increases over the treatment period in the ivabradine group in comparison with the placebo group in E, total mitral flow duration and LAVI. Findings on the KCCQ changed minimally in both treatment groups. Most patients (78.2% vs. 83.3%) showed no change in NYHA class at the last post-baseline visit although improvements were seen in 13 (14.9%) ivabradine group patients and in seven (8.3%) placebo group patients, and worsenings in six (6.9%) ivabradine group patients and seven (8.3%) placebo group patients.
Safety
Adverse events are reported in Table 4 . There were no statistically significant differences between the groups in the occurrence of adverse events (P = 0.633) or in treatment discontinuation caused . by the occurrence of adverse events (P = 0.261). The number of episodes of atrial fibrillation was comparable across the groups and no other relevant safety concerns were identified. Three deaths were reported in the ivabradine group, compared with none in the placebo group; none were considered to be drug-related.
Discussion
In this study we investigated the effects of the I f current inhibitor ivabradine, vs. placebo, in patients with chronic stable HFpEF a Two deaths occurred in the ivabradine group as fatal outcomes of ischaemic stroke and acute pulmonary oedema at, respectively, 4 days and 151 days after treatment withdrawal. One death occurred in the ivabradine group as a fatal outcome of diffuse large B cell lymphoma. None were considered to have been related to treatment. b All of these patients had a history of hypertension and in most cases a worsening of this condition was reported.
over an 8-month treatment period. The patients were selected according to the 2012 Heart Failure Guidelines of the European Society of Cardiology 15 and the sample appeared to conform well to the intended target population.
After 8 months of treatment, no evidence of improvement was found in any of the three co-primary endpoints. Firstly, although E/e ′ , which reflects left ventricular filling pressure, was slightly increased in the ivabradine group and slightly decreased in the placebo group, the difference between the two groups was not statistically significant. The initial hypothesis, that a decrease in HR would be associated with a decrease in left ventricular filling pressure, was not confirmed. Secondly, the distance covered during the 6MWT showed no change in the active group. Thirdly, no change in the plasma concentration of NT-proBNP was observed in either group.
We did indeed find that a decrease in HR (of about 13 b.p.m. in the ivabradine group) was associated with longer left ventricular filling time with significant increases in peak early filling velocity. However, these changes were not associated with improvements in left ventricular relaxation (no significant increase in mean e ′ ). Therefore, E/e ′ was not reduced, reflecting no improvement in left ventricular filling.
The increase in atrial volume was probably related to the increased duration of the cardiac cycle. There was no change in left ventricular mass or in arterial-ventricular coupling assessed by the Ea/Ees ratio.
Three hypotheses can be put forward to explain the failure to demonstrate any benefit of ivabradine in HFpEF patients. Firstly, the population enrolled had rather advanced HFpEF with extensive myocardial fibrosis that allowed only a poor response to pharmacological intervention (i.e. subjects were too sick to benefit). In cases of extensive fibrosis with predominant restriction and no or minimal stroke volume reserve, cardiac output is entirely dependent on HR. with predominant relaxation abnormalities and HFpEF with predominant restriction abnormalities. Secondly, the trial had a high rate of screening failures and recruitment was halted before the target was reached. Hence, the study was underpowered, but there was no trend towards benefit in any of the three co-primary endpoints. Thirdly, the hypothesis that lowering HR would facilitate an increase in filling time in stiff ventricles and as a result induce a reverse remodelling was not verified. Given the present evidence, EDIFY does not support the concept that HR reduction is beneficial in HFpEF, at least in patients with the current profile. This differs from findings in HFrEF, in which the SHIFT study demonstrated significant improvements in cardiovascular outcomes and an anti-remodelling effect as a result of ivabradine treatment, including when HFrEF was associated with severe diastolic dysfunction. 6, 7, 16 This may be explained by the fact that HFpEF and HFrEF have different patterns of myocardial remodelling arising from their different pathophysiological mechanisms. 17, 18 Some evidence points towards the stronger involvement of systemic inflammation associated with HFpEF, which may also impact the remodelling process.
19,20
The present study was limited by the inclusion of a sample size lower than that planned as a result of the high rate of screening failure. The included population may not reflect all of the numerous phenotypes described in this heterogeneous condition. In addition, we enrolled only patients in sinus rhythm in view of the mechanism of action of ivabradine. The strengths of this study include its application of a rigorous selection process and the centralized reading of echocardiography assessments.
Conclusions
In the EDIFY study population, HR reduction with ivabradine did not show a beneficial effect on cardiac filling pressures (E/e ′ ), exercise capacity (6MWT) and plasma NT-proBNP concentrations over 8 months. These findings do not support the use of ivabradine in this group of patients with HFpEF. Further studies may look at whether some particular phenotypes of HFpEF may benefit from HR reduction.
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